VRDN

Viridian Therapeutics, Inc. (VRDN) - 2025 Annual Report Summary

Business Context and Reporting Period

This summary covers the fiscal year ended December 31, 2025. Viridian Therapeutics is a biopharmaceutical company focused on developing best-in-class medicines for serious and rare diseases, primarily targeting Thyroid Eye Disease (TED) and autoimmune disorders via FcRn inhibition. The company has no approved products and generates revenue solely from collaboration and license agreements.

Key Financial Metrics

Note: Revenue in 2025 was driven primarily by a $70.0 million upfront payment from a new collaboration agreement with Kissei Pharmaceutical Co., Ltd.

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased from $0.3 million in 2024 to $70.8 million in 2025, primarily due to the $70.0 million upfront license fee from Kissei. Collaboration revenue from related parties (Zenas/Zai Lab) also increased slightly.
• Increased Operating Loss: Net loss widened by $72.7 million to $342.6 million. This was driven by a $100.7 million increase in Research and Development (R&D) expenses and a $34.2 million increase in Selling, General, and Administrative (SG&A) expenses.
• R&D Expense Drivers: Direct costs for the TED portfolio increased by $78.3 million due to Phase 3 clinical trials for veligrotug and elegrobart, plus an $11.4 million milestone payment to ImmunoGen.
• SG&A Expense Drivers: Increased by $34.2 million, largely due to personnel costs for commercial preparation and legal/professional fees related to the Kissei deal and commercial readiness.
• Financing Activity: The company raised significant capital through public offerings ($289.1 million gross proceeds in Oct 2025), ATM offerings ($61.8 million net), and debt financing ($55.0 million from DRI and $28.4 million from Hercules).

Guidance, Outlook, and Management Commentary

• Veligrotug (IV IGF-1R): Submitted a Biologics License Application (BLA) to the FDA in October 2025. Granted Priority Review with a PDUFA target action date of June 30, 2026. Submitted a Marketing Authorization Application (MAA) to the EMA in January 2026. Phase 3 trials (THRIVE and THRIVE-2) met all primary and secondary endpoints.
• Elegrobart (SC IGF-1R): Completed enrollment in Phase 3 trials (REVEAL-1 and REVEAL-2) in September 2025, exceeding targets. Topline data expected in Q1 and Q2 2026, respectively. An auto-injector study was completed in December 2025.
• FcRn Inhibitors: VRDN-006 Phase 1 data announced in September 2025 showed consistent IgG reduction and safety. VRDN-008 IND cleared in January 2026; healthy volunteer data expected in H2 2026.
• Liquidity: Management expects current cash resources ($874.7 million) plus potential near-term milestones ($115.0 million from DRI) and anticipated commercial revenues to fund operations for at least 12 months and potentially to break-even if approvals are received on schedule.
• Risks: Key risks include the potential for FDA delays due to government shutdowns or staffing issues, failure to achieve regulatory approval, manufacturing reliance on a single CDMO (WuXi Biologics), and the impact of the BIOSECURE Act on Chinese suppliers.

Investor Verification Checklist

• Regulatory Timeline: Verify the status of the veligrotug BLA review and the June 30, 2026 PDUFA date, considering potential FDA operational disruptions.
• Clinical Data Readouts: Monitor the Q1/Q2 2026 topline data announcements for elegrobart (REVEAL-1 and REVEAL-2) to confirm efficacy and safety profiles.
• Manufacturing Supply Chain: Assess the company's progress in diversifying manufacturing away from WuXi Biologics in light of the BIOSECURE Act and geopolitical tensions.
• Debt Covenants: Review the terms of the DRI Purchase and Sale Agreement and Hercules Loan, specifically the milestones required to unlock the remaining $245 million (DRI) and $250 million (Hercules) in potential funding.
• Commercial Readiness: Evaluate the company's ability to build a sales force and secure payer coverage for veligrotug if approved in mid-2026.